teaser
Sweden’s Medivir has been told that partner Bristol-Myers Squibb has terminated development of the firms’ preclinical HIV compound MIV-170.
The decision was taken “because the compound did not meet the profile desired” by the New York-based drugs major. The Swedish firm noted that MIV-170 belongs to a group
